{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:40:17Z","timestamp":1782351617507,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T00:00:00Z","timestamp":1324425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T00:00:00Z","timestamp":1324425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00296-011-2212-4","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T07:09:47Z","timestamp":1324364987000},"page":"1351-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease"],"prefix":"10.1007","volume":"33","author":[{"given":"Aziza","family":"Mounach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmae","family":"Rezqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrazak","family":"Nouijai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Ghozlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahsen","family":"Achemlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdellah El","family":"Maghraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,21]]},"reference":[{"key":"2212_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldman","year":"1996","unstructured":"Feldman M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397\u2013440","journal-title":"Annu Rev Immunol"},{"key":"2212_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF00832003","volume":"20","author":"FM Brennan","year":"1998","unstructured":"Brennan FM, Maini RN, Feldman M (1998) Role of proinflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 20:133\u2013147","journal-title":"Springer Semin Immunopathol"},{"key":"2212_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF01782262","volume":"44","author":"J Neidel","year":"1995","unstructured":"Neidel J, Schulze M, Lindschau J (1995) Association between degree of bone erosion and synovial fluid levels of tumor necrosis factor \u03b1 in the knee joints of patients with rheumatoid arthritis. Inflamm Res 44:217\u2013221","journal-title":"Inflamm Res"},{"key":"2212_CR4","first-page":"618","volume":"103","author":"JL Lan","year":"2004","unstructured":"Lan JL, Chou SJ, Chen DY et al (2004) A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 5-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 103:618\u2013623","journal-title":"J Formos Med Assoc"},{"key":"2212_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"2212_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"},{"key":"2212_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499\u2013505","journal-title":"Arthritis Rheum"},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/art.1780310816","volume":"31","author":"T Saxne","year":"1988","unstructured":"Saxne T, Palladino MA Jr et al (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041\u20131045","journal-title":"Arthritis Rheum"},{"key":"2212_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.1780340908","volume":"34","author":"CQ Chu","year":"1991","unstructured":"Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125\u20131132","journal-title":"Arthritis Rheum"},{"key":"2212_CR10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1358\/dot.1999.35.12.564038","volume":"35","author":"K Asadullah","year":"1999","unstructured":"Asadullah K, Docke WD, Volk HD, Sterry W (1999) The pathophysiological role of cytokines in psoriasis. Drugs Today 35:913\u2013924","journal-title":"Drugs Today"},{"key":"2212_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/03009740701288173","volume":"36","author":"A Delle Sedie","year":"2007","unstructured":"Delle Sedie A, Bazzichi L, Bombardieri S, Riente L (2007) Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol 36:403\u2013404","journal-title":"Scand J Rheumatol"},{"key":"2212_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000235582","volume":"219","author":"A Esmailzadeh","year":"2009","unstructured":"Esmailzadeh A et al (2009) Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 219:163\u2013167","journal-title":"Dermatology"},{"key":"2212_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","volume":"61","author":"A Asarch","year":"2009","unstructured":"Asarch A et al (2009) Lichen-planus-like eruptions: an emerging side effect of tumor necrosis factor alpha antagonists. J Am Acad Dermatol 61:104\u2013111","journal-title":"J Am Acad Dermatol"},{"key":"2212_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U et al (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1\u201314","journal-title":"Am J Clin Dermatol"},{"key":"2212_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"},{"key":"2212_CR16","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdock RJ, Weinberg MA (2005) Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"2212_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1365-2036.2008.03919.x","volume":"29","author":"GT Ho","year":"2009","unstructured":"Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-Jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J (2009) Efficacy and complications of adalimumab treatment for medically refractory Crohn\u2019s disease: analysis of nationwide experience in Scotland (2004\u20132008). Aliment Pharmacol Ther 29:527\u2013534","journal-title":"Aliment Pharmacol Ther"},{"key":"2212_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92\u201396","journal-title":"Arch Dermatol"},{"key":"2212_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2332\/allergolint.55.27","volume":"55","author":"JC Roujeau","year":"2006","unstructured":"Roujeau JC (2006) Immune mechanisms in drug allergy. Allergol Int 55:27\u201333","journal-title":"Allergol Int"},{"key":"2212_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drudis.2006.11.013","volume":"12","author":"WM Kooloos","year":"2007","unstructured":"Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ (2007) Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn\u2019s disease. Drug Discov Today 12:125\u2013131","journal-title":"Drug Discov Today"},{"key":"2212_CR21","first-page":"1269","volume":"65","author":"M Yamamura","year":"2007","unstructured":"Yamamura M (2007) Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis\u2014efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 65:1269\u20131275","journal-title":"Nippon Rinsho"},{"key":"2212_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2217\/14622416.8.7.761","volume":"8","author":"MJ Coenen","year":"2007","unstructured":"Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B (2007) Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8:761\u2013773","journal-title":"Pharmacogenomics"},{"key":"2212_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/14622416.6.5.481","volume":"6","author":"P Ranganathan","year":"2005","unstructured":"Ranganathan P (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6:481\u2013490","journal-title":"Pharmacogenomics"},{"key":"2212_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactosealpha-1,3-galactose. N Engl J Med 358:1109\u20131117","journal-title":"N Engl J Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-011-2212-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2212-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T23:30:29Z","timestamp":1686526229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-011-2212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,21]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-2212-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,21]]},"assertion":[{"value":"28 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}